News
A Roth IRA might not be the flashiest way to spend your summer job money, but saving even a small portion of your paycheck could net...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
News
This article was written by Follow Alberto holds a Master’s degree in Business Economics. During his academic career he acquired an extensive managerial and...
News
This article was written by Follow As a tech-focused industry Research Analyst, I aim to provide differentiated insights, whether it is for investing, trading,...
News
This article was written by Follow Full time trader and investor. Instead of lengthy and boring articles, I prefer writing concise arguments about value...
News
This article was written by B.A., M.A., University of Pennsylvania,; M.A., (Oxon.); Ph.D. Princeton University Currently CEO of WWS Swiss Financial Consulting SA Analyst’s...
News
America’s car dealers ended the second quarter with more than 92,000 electric vehicles on dealer lots awaiting sale. A year ago, they had 21,000....
News
Introduction I always like to start my articles, when I can, by reviewing any previous coverage I’ve had of a stock. In Fidelity National...
News
The average borrower taking out a used car loan in the first quarter of 2023 borrowed 125% of the value of the car they...
News
With the S&P 500 hovering around 12-month highs despite macro jitters, a common question investors are asking is: is it too late to get...
News
Amid stiff competition in a generally saturated market, American oral care giant Colgate-Palmolive (NYSE:CL) has delivered marginal growth over the past several years. A...
News
These 3 are smaller than the competition, make no mistake they bring a lot to the table I used the words revenge of the...
News
Introduction Aldeyra Therapeutics (NASDAQ:ALDX) is a biotech firm focused on creating therapies for immune-mediated diseases. Their groundbreaking RASP (reactive aldehyde species) pharmaceutical platform targets...
News
On July 6, 2023, the Food and Drug Administration granted full approval to Biogen (NASDAQ:BIIB) and Eisai’s (OTCPK:ESALF, OTCPK:ESAIY) anti-amyloid antibody drug Leqembi. For...
